Chanan-Khan A - Search Results

1

Plasma cell leukaemia and other aggressive plasma cell malignancies.

Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Sher T, et al. Br J Haematol. 2010 Aug;150(4):418-27. doi: 10.1111/j.1365-2141.2010.08157.x. Br J Haematol. 2010. PMID: 20701603 Free PMC article. Review.

2

Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDS.

Bernstein ZP, Brooks SP, Chanan-Khan A, Gollnick SO, Gilbert MJ, Miller KC, Tomasi TB. Bernstein ZP, et al. HIV Clin Trials. 2002 May-Jun;3(3):219-24. doi: 10.1310/HP8B-NF27-VFWA-80YX. HIV Clin Trials. 2002. PMID: 12032880 Clinical Trial.

3

A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma.

Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. Bernstein ZP, et al. Cancer. 2002 Dec 15;95(12):2555-61. doi: 10.1002/cncr.11009. Cancer. 2002. PMID: 12467070 Free article. Clinical Trial.

4

Bcl-2 antisense therapy in B-cell malignant proliferative disorders.

Chanan-Khan A, Czuczman MS. Chanan-Khan A, et al. Curr Treat Options Oncol. 2004 Aug;5(4):261-7. doi: 10.1007/s11864-004-0017-3. Curr Treat Options Oncol. 2004. PMID: 15233903 Review.

5

Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAART.

Srinivasan S, Takeshita K, Holkova B, Czuczman MS, Miller K, Bernstein ZP, Driscoll D, Chanan-Khan A. Srinivasan S, et al. HIV Clin Trials. 2004 May-Jun;5(3):140-5. doi: 10.1310/BDHX-D9BC-YWVU-9NBR. HIV Clin Trials. 2004. PMID: 15248138

6

Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.

Chanan-Khan A, Islam T, Alam A, Miller KC, Gibbs J, Barcos M, Czuczman MS, Paplham P, Hahn T, McCarthy P. Chanan-Khan A, et al. Leuk Lymphoma. 2004 Aug;45(8):1673-5. doi: 10.1080/10428190310001609924. Leuk Lymphoma. 2004. PMID: 15370223

7

Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.

Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS. Ramanarayanan J, et al. Br J Haematol. 2004 Dec;127(5):519-30. doi: 10.1111/j.1365-2141.2004.05239.x. Br J Haematol. 2004. PMID: 15566355 Free article.

8

Bcl-2 antisense therapy in B-cell malignancies.

Chanan-Khan A. Chanan-Khan A. Blood Rev. 2005 Jul;19(4):213-21. doi: 10.1016/j.blre.2004.11.002. Epub 2005 Jan 5. Blood Rev. 2005. PMID: 15784299 Review.

9

Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.

Chanan-Khan A, Miller KC. Chanan-Khan A, et al. Leuk Lymphoma. 2005 Jul;46(7):1103-4. doi: 10.1080/10428190500097086. Leuk Lymphoma. 2005. PMID: 16019567 No abstract available.

10

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczman MS. Chanan-Khan A, et al. Blood. 2005 Nov 15;106(10):3348-52. doi: 10.1182/blood-2005-02-0669. Epub 2005 Jul 28. Blood. 2005. PMID: 16051743 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

233 results

Search Page